Cipla Ltd (NSE:CIPLA) plans a Q2 FY2026/27 U.S. launch of the first dry‑powder inhaler from its U.S. plant after FDA ANDA approval for all three strengths of generic Advair Diskus into a ~$908M market, even as Q1 net profit fell 34% YoY despite revenue growth.
Previous Week Recap
- Cipla Ltd: FDA ANDA Approval For Advair Diskus: Cipla Ltd (CIPLA) won US FDA ANDA approval for generic Advair Diskus (all three strengths). First US dry‑powder inhaler from Cipla’s US plant; launch planned Q2 FY2026‑27. US market ~$908M
- Cipla Ltd: Q1 Net Profit Falls 34%: Cipla Ltd (CIPLA) Q1 net profit fell 34% YoY as a prior-year Revlimid gain wasn’t repeated, despite revenue rising in the quarter.
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.